- Collaboration follows data from ANGEL-MS extension to Phase 2 MS trial
- Aims to address key unmet need of slowing or stopping disease progression
Geneva, Switzerland, November 25, 2019 – 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), announced today a collaboration for a new clinical trial of temelimab in multiple sclerosis (MS) with clinical researchers of Karolinska Institutet and the Academic Specialist Center (ASC), Stockholm, Sweden. This single-center study will be led by Dr. Fredrik Piehl, Professor of Neurology at the Department of Clinical Neurosciences of the Karolinska Institutet, and head of research at the MS clinic at ASC.
For more information,
https://www.geneuro.com/data/news/GN-ASC-PR-FINAL.pdf
